- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
The State of Medical Marijuana in Washington
2020 Grade: B-
2019-2020 Improvements and Recommendations
The 2019 legislative session saw a suite of new medical cannabis laws designed to benefit the state’s registered patient population. Included in these measures was legislation exempting qualifying cannabis patients from in-person physical examinations in order to renew their annual registration, as well as a measure allowing patients to consume cannabis products on school grounds, school buses and at school events.
The state also passed legislation to align Washington’s hemp program with the 2018 Farm Bill, which transitioned the national hemp pilot production program into a permanent program under the USDA. Comprehensive regulations for a state-governed commercial hemp program will benefit patients by improving the diversity of hemp-derived CBD products and associated product testing regime to ensure product quality and patient safety standards are met.
Washington maintained patient access during COVID by authorizing medical cannabis businesses to continue operating, and permitted preordering and curbside pickup. The state already had provisions in place allowing patient evaluations to be conducted via telehealth. ASA recommends permanently maintaining COVID temporary rules.
ASA urges Washington lawmakers to take up legislation proposed by the Liquor and Cannabis Control Board that would redistribute unused or retired medical retail licences to increase the number of locations for patients to access. Another bill ASA hopes lawmakers can take up in 2021 would allow tier-one cultivators to sell medical-grade cannabis directly to registered state patients. Such a measure could expand medical cannabis availability for patients.
In 1998, Washington voters approved state Initiative Measure No. 692, allowing a qualifying patient or designated provider to have a 60-day supply of medical cannabis, later defined as 24 ounces and 15 plants. Under the measure qualifying patients and caregivers within those limits are protected from arrest and prosecution, and a patient who exceeds those limits is entitled to a medical defense of medical necessity. Designated providers must be 18 years of age or older.
Legal retail access for patients at dispensaries was not permitted under Washington law until voters approved I-502 authorizing an adult-use commercial cannabis program in 2012. However Washington did allow patients participating in cooperatives to grow cannabis, and these provisions of the state’s medical cannabis laws remain in place today. Acknowledging the lack of insurance options available to subsidize the costs of medical cannabis, the state shields cannabis patients from state and local taxes applied to legal cannabis at retail establishments.
In 2017, Washington passed SB 5131, which provided a slight improvement to Washington’s medical access market. The bill allows qualifying medical card holders in the state database to purchase immature plants, clones, and seeds directly from licensed cultivators authorized by the state to conduct these activities. SB 5131 also implemented a few technical changes, including provisions related to consulting agreements, advertising restrictions, research, and qualifications for organic cannabis.
In 2018, regulators released new packaging and labeling requirements, as well as the state’s first research license. In 2019, the state temporarily suspended the requirement that cannabis products be tested for heavy metal because there were no labs certified to do so. A lack of laboratory testing creates an enormous safety problem for patients. While there was only a temporary period where heavy metal testing was suspended, any time where legal products are untested and made available to patients is too long.
Surveyed patients report wanting more dispensaries available to improve access. Some would like to see better quality standards for medical cannabis enacted into law. Other surveyed patients would like to see the temporary COVID pre-ordering and curbside pickup regulations maintained in the future.